Showing 7101-7110 of 8818 results for "".
- When Lightning Strikes: A Case Study of Staphylococcal Scalded Skin Syndrome in a 55-year-old Manhttps://practicaldermatology.com/news/when-lightning-strikes-a-case-study-of-staphylococcal-scalded-skin-syndrome-in-a-55-year-old-man/2462042/Five months after being struck by lightning, a 55-year-old male presented with a 2-day history of an erythematous rash. The patient noted his skin had been excessively dry since the lightning strike, and he recently added a new essential oil to his bath. His medical history includes liver failure
- Regenerative Medicine Breakthrough: Researchers Create BioPrinted Full Thickness Skinhttps://practicaldermatology.com/news/regenerative-medicine-breakthrough-researchers-create-bioprinted-full-thickness-skin/2462041/New bioprinted skin may accelerate wound healing, support healthy extracellular matrix remodeling, and aid in complete wound recovery, according to research out of the Wake Forest Institute for Regenerative Medicine (WFIRM). Available grafts are often temporary, or if permanent, h
- Revealed: Key Genes That May Up Nodular Melanoma Riskhttps://practicaldermatology.com/news/revealed-key-genes-that-may-up-nodular-melanoma-risk/2462038/New research sheds light on gene variants which may contribute to higher risk for nodular melanoma. Nodular melanoma accounts for around 14% of invasive melanoma cases, but the aggressive subtype is the largest contributor to melanoma deaths. “Nodular melanoma is often detect
- Nevisense Detects Skin Barrier Damage In Skin Sampleshttps://practicaldermatology.com/news/nevisense-detects-skin-barrier-damage-in-skin-samples/2462031/Nevisense can measure skin barrier function in human excised skin samples, SciBase reports. For the study, Nevisense and its underlying Electrical Impedance Spectroscopy (EIS) technology were used to assess the effect of commercially available detergents on the skin barrier of mice
- Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262https://practicaldermatology.com/news/escient-pharmaceuticals-initiates-clinical-proof-of-concept-study-of-ep262/2462020/The first patient has been dosed in Escient Pharmaceuticals CALM-CIndU, an open label Phase 1b clinical proof-of-concept study of EP262, a first-in-class oral MRGPRX2 antagonist for chronic inducible urticaria. By blocking activation of MRGPRX2 and degranulation of mast cells,
- Exploring the Link Between Sex Hormones and Melanoma Riskhttps://practicaldermatology.com/news/exploring-the-link-between-sex-hormones-and-melanoma-risk/2462016/Researchers out of the University of Tennessee Health Science Center are beginning a study to determine whether sex hormones affect the risk of melanoma The team received a $423,500 grant from the National Institute of Environmental Health Sciences, part of the National Institutes of He
- Smart Ring May Objectively Measure Scratching Intensityhttps://practicaldermatology.com/news/smart-ring-may-objectively-measure-scratching-intensity/2462015/A new wearable device may objectively measure the intensity of scratching. Akhil Padmanabha, a PhD student in Carnegie Mellon University's (CMU)
- CeraVe Funds New Derm Residency Position at George Washington Universityhttps://practicaldermatology.com/news/cerave-funds-new-derm-residency-position-at-george-washington-university/2462012/CeraVe is partnering with George Washington University to support a newly approved Accreditation Council for Graduate Medical Education (ACGME) residency spot in the school's Department of Dermatology Resident Program, slated to begin on July 1, 2024. "
- Positive Topline Results Seen for Roflumilast Cream 0.05% in Young Kidshttps://practicaldermatology.com/news/positive-topline-results-seen-for-roflumilast-cream-005-in-young-kids/2462010/Arcutis Biotherapeutics, Inc.’s roflumilast cream 0.05% met all primary endpoint and all secondary endpoints in children aged 2 to 5 years with mild to moderate atopic dermatitis (AD), according to results from the INTEGUMENT-PED pivotal Phase 3 trial. In
- Encouraging Preclinical Results Seen for Scinai’s NanoAbs in Plaque Psoriasishttps://practicaldermatology.com/news/encouraging-preclinical-results-seen-for-scinais-nanoabs-in-plaque-psoriasis/2462006/Scinai Immunotherapeutics Ltd.’s anti‑interleukin 17 (IL‑17) NanoAbs downregulated key molecular markers that are overexpressed in plaque psoriasis, according to preclinical data relased by Scinai. Results from ex-vivo study in human psoriatic skin anticipated in Q4 2023; In-